Trial Profile
A 36-week, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Efficacy and Safety of PXL065 Versus Placebo in Noncirrhotic Biopsy-proven NonAlcoholic SteatoHepatitis (NASH) Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Pioglitazone deuterated (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms DESTINY 1
- Sponsors Poxel
- 15 Mar 2023 According to a Poxel media release, the company will present positive results from this trial at the NASH Renaissance virtual event hosted by Evercore ISI 2023.
- 07 Mar 2023 Results presented in a Poxel Media Release.
- 17 Feb 2023 Results published in the Journal of Hepatology